Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains

Journal of Microbiological Methods

Volumn 57, Issue 2, 2004, Pages 231-239

  Bernard, Louis ^a   Vaudaux, Pierre ^a   Rohner, Peter ^a   Huggler, Elzbieta ^a   Armanet, Mathieu ^a   Pittet, Didier ^a   Lew, Daniel P ^a   Schrenzel, Jacques ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Glycopeptide susceptibility; Methicillin resistant Staphylococcus aureus strains; Vancomycin

Indexed keywords

GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN;

ACCURACY; AGAR MEDIUM; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SENSITIVITY; INFUSION; INOCULATION; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; TIME SERIES ANALYSIS; VALIDATION PROCESS;

ANTI-BACTERIAL AGENTS; BLOOD; DNA FINGERPRINTING; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; EPIDEMIOLOGY, MOLECULAR; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 1842457658     PISSN: 01677012     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mimet.2004.01.012     Document Type: Article

References (36)

1. Ariza J., Pujol M., Cabo J., Peña C., Fernández N., Liñares J., Ayats J., Gudiol F. Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet. 353:1999;1587-1588.
2. Bert F., Clarissou J., Durand F., Delefosse D., Chauvet C., Lefebvre P., Lambert N., Branger C. Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J. Clin. Microbiol. 41:2003;5147-5152.
3. Blanc D.S., Struelens M.J., Deplano A., De Ryck R., Hauser P.M., Petignat C., Francioli P. Epidemiological validation of pulsed-field gel electrophoresis patterns for methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 39:2001;3442-3445.
4. Blanc D.S., Pittet D., Ruef C., Widmer A.F., Muhlemann K., Petignat C., Harbarth S., Auckenthaler R., Bille J., Frei R., Zbinden R., Moreillon P., Sudre P., Francioli P. Molecular epidemiology of predominant clones and sporadic strains of methicillin resistant Staphylococcus aureus in Switzerland and comparison with European epidemic clones. Clin. Microbiol. Infect. 8:2002;419-426.
5. Chang S., Sievert D.M., Hageman J.C., Boulton M.L., Tenover F.C., Downes F.P., Shah S., Rudrik J.T., Pupp G.R., Brown W.J., Cardo D., Fridkin S.K. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:2003;1342-1347.
6. Denis O., Nonhoff C., Byl B., Knoop C., Bobin-Dubreux S., Struelens M.J. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J. Antimicrob. Chemother. 50:2002;383-391.
7. Deplano A., Witte W., Van Leeuwen W.J., Brun Y., Struelens M.J. Clonal dissemination of epidemic methicillin-resistant Staphylococcus aureus in Belgium and neighboring countries. Clin. Microbiol. Infect. 6:2000;239-245.
8. Elsaghier A.A., Aucken H.M., Hamilton-Miller J.M., Shaw S., Kibbler C.C. Resistance to teicoplanin developing during treatment of methicillin-resistant Staphylococcus aureus infection. J. Antimicrob. Chemother. 49:2002;423-424.
9. Fridkin S.K., Hageman J., McDougal L.K., Mohammed J., Jarvis W.R., Perl T.M., Tenover F.C. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36:2003;429-439.
10. Geisel R., Schmitz F.J., Fluit A.C., Labischinski H. Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur. J. Clin. Microbiol. Infect. Dis. 20:2001;685-697.
11. Goldstein F.W., Kitzis M.D. Vancomycin-resistant Staphylococcus aureus: no apocalypse now. Clin. Microbiol. Infect. 9:2003;761-765.
12. Guerin F., Buu-Hoi A., Mainardi J.L., Kac G., Colardelle N., Vaupre S., Gutmann L., Podglajen I. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. J. Clin. Microbiol. 38:2000;2985-2988.
13. Hageman J.C., Pegues D.A., Jepson C., Bell R.L., Guinan M., Ward K.W., Cohen M.D., Hindler J.A., Tenover F.C., McAllister S.K., Kellum M.E., Fridkin S.K. Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. Emerg. Infect. Dis. 7:2001;1023-1025.
14. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet, Infect. Dis. 1:2001;147-155.
15. Hiramatsu K., Aritaka N., Hanaki H., Kawasaki S., Hosoda Y., Hori S., Fukuchi Y., Kobayashi I. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 350:1997;1670-1673.
16. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:1997;135-136.
17. Hubert S.K., Mohammed J.M., Fridkin S.K., Gaynes R.P., McGowan J.E.J., Tenover F.C. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals. J. Clin. Microbiol. 37:1999;3590-3593.
18. Kantzanou M., Tassios P.T., Tseleni-Kotsovili A., Legakis N.J., Vatopoulos A.C. Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 43:1999;729-731.
19. Linares J. The VISA/GISA problem: therapeutic implications. Clin. Microbiol. Infect. 7(Suppl. 4):2001;8-15.
20. Manuel R.J., Tuck A., Lowes A., Pallett A. Detection of teicoplanin resistance in UK EMRSA-17 strains. J. Antimicrob. Chemother. 50:2002;1089-1090.
21. Moore M.R., Perdreau-Remington F., Chambers H.F. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob. Agents Chemother. 47:2003;1262-1266.
22. Naimi T.S., Anderson D., O'Boyle C., Boxrud D.J., Johnson S.K., Tenover F.C., Lynfield R. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. Clin. Infect. Dis. 36:2003;1609-1612.
23. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 7th ed. Approved standard M2-A7. National Committee for Clinical Laboratory Standards. Wayne, PA, 2000.
24. Paton R., Snell T., Emmanuel F.X., Miles R.S. Glycopeptide resistance in an epidemic strain of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 48:2001;941-942.
25. Pfeltz R.F., Singh V.K., Schmidt J.L., Batten M.A., Baranyk C.S., Nadakavukaren M.J., Jayaswal R.K., Wilkinson B.J. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob. Agents Chemother. 44:2000;294-303.
26. Ploy M.C., Grelaud C., Martin C., de Lumley L., Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet. 351:1998;1212.
27. Sieradzki K., Roberts R.B., Haber S.W., Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med. 340:1999;517-523.
28. Sieradzki K., Leski T., Dick J., Borio L., Tomasz A. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J. Clin. Microbiol. 41:2003;1687-1693.
29. Smith T.L., Pearson M.L., Wilcox K.R., Cruz C., Lancaster M.V., Robinson-Dunn B., Tenover F.C., Zervos M.J., Band J.D., White E., Jarvis W.R. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340:1999;493-501.
30. Struelens M.J. Consensus guidelines for appropriate use and evaluation of microbial epidemiologic typing systems. Clin. Microbiol. Infect. 2:1996;2-11.
31. Tenover F.C., Lancaster M.V., Hill B.C., Steward C.D., Stocker S.A., Hancock G.A., O'Hara C.M., Clark N.C., Hiramatsu K. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1998;1020-1027.
32. Tenover F.C., Biddle J.W., Lancaster M.V. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg. Infect. Dis. 7:2001;327-332.
33. Van Griethuysen A., Van 't Veen A., Buiting A., Walsh T., Kluytmans J. High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands. J. Clin. Microbiol. 41:2003;2487-2491.
34. Walsh T.R., Howe R.A. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu. Rev. Microbiol. 56:2002;657-675.
35. Walsh T.R., Bolmström A., Qwärnström A., Ho P., Wootton M., Howe R.A., MacGowan A.P., Diekema D. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2001;2439-2444.
36. Wootton M., Howe R.A., Hillman R., Walsh T.R., Bennett P.M., MacGowan A.P. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:2001;399-403.